BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 18556884)

  • 21. Hereditary breast/ovarian cancer--pitfalls in genetic counseling.
    Dagan E; Gershoni-Baruch R
    Clin Genet; 2001 Oct; 60(4):310-3. PubMed ID: 11683778
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hereditary breast and ovarian cancer syndrome and issues in pediatric and adolescent practice.
    Herman JD; Appelbaum H
    J Pediatr Adolesc Gynecol; 2010 Aug; 23(4):253-8. PubMed ID: 20632459
    [No Abstract]   [Full Text] [Related]  

  • 23. Contribution of BRCA2 germline mutations to hereditary breast/ovarian cancer in Germany.
    Hamann U; Liu X; Lange S; Ulmer HU; Benner A; Scott RJ
    J Med Genet; 2002 Mar; 39(3):E12. PubMed ID: 11897832
    [No Abstract]   [Full Text] [Related]  

  • 24. Hereditary breast-ovarian cancer: clinical findings and medical management.
    Marshall M; Solomon S
    Plast Surg Nurs; 2007; 27(3):124-7. PubMed ID: 17901820
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Breast & ovarian cancer. Issues in risk assessment.
    Caro SW
    Adv Nurse Pract; 1999 Aug; 7(8):26-32; quiz 33-4. PubMed ID: 10745719
    [No Abstract]   [Full Text] [Related]  

  • 26. Receiving inconclusive genetic test results: an interpretive description of the BRCA1/2 experience.
    Maheu C; Thorne S
    Res Nurs Health; 2008 Dec; 31(6):553-62. PubMed ID: 18449940
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Familial breast and ovarian cancer: genetic counseling and clinical management in Italy.
    Pasini B; Pierotti MA
    Dis Markers; 1999 Oct; 15(1-3):41-3. PubMed ID: 10595250
    [No Abstract]   [Full Text] [Related]  

  • 28. Genomic rearrangements in the BRCA1 and BRCA2 genes.
    Mazoyer S
    Hum Mutat; 2005 May; 25(5):415-22. PubMed ID: 15832305
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Unprepared, understaffed, and unplanned: thoughts on the practical implications of discovering new breast and ovarian cancer causing genes.
    Resta RG
    J Genet Couns; 2009 Dec; 18(6):521-3. PubMed ID: 19798552
    [No Abstract]   [Full Text] [Related]  

  • 30. [Inherited breast and ovarian cancers].
    Gerdes AM; Ejlertsen B
    Ugeskr Laeger; 2006 Jun; 168(24):2367-9. PubMed ID: 16822422
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phenotypic expression of double heterozygosity for BRCA1 and BRCA2 germline mutations.
    Leegte B; van der Hout AH; Deffenbaugh AM; Bakker MK; Mulder IM; ten Berge A; Leenders EP; Wesseling J; de Hullu J; Hoogerbrugge N; Ligtenberg MJ; Ardern-Jones A; Bancroft E; Salmon A; Barwell J; Eeles R; Oosterwijk JC
    J Med Genet; 2005 Mar; 42(3):e20. PubMed ID: 15744030
    [No Abstract]   [Full Text] [Related]  

  • 32. Missense polymorphisms in BRCA1 and BRCA2 and risk of breast and ovarian cancer.
    Dombernowsky SL; Weischer M; Freiberg JJ; Bojesen SE; Tybjaerg-Hansen A; Nordestgaard BG
    Cancer Epidemiol Biomarkers Prev; 2009 Aug; 18(8):2339-42. PubMed ID: 19661094
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical considerations in the management of individuals at risk for hereditary breast and ovarian cancer.
    Robson ME
    Cancer Control; 2002; 9(6):457-65. PubMed ID: 12514563
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The impact of proband mediated information dissemination in families with a BRCA1/2 gene mutation.
    Sermijn E; Goelen G; Teugels E; Kaufman L; Bonduelle M; Neyns B; Poppe B; De Paepe A; De Grève J
    J Med Genet; 2004 Mar; 41(3):e23. PubMed ID: 14985394
    [No Abstract]   [Full Text] [Related]  

  • 35. BRCA1: genetic testing and hereditary breast and ovarian cancer.
    Ross DW
    Arch Pathol Lab Med; 1997 Jul; 121(7):754-5. PubMed ID: 9240915
    [No Abstract]   [Full Text] [Related]  

  • 36. [Management of families at high risk for hereditary breast-ovarian cancers: the endocrinologist's point of view].
    Courtillot C; Touraine P
    Ann Endocrinol (Paris); 2008 Jun; 69(3):193-200. PubMed ID: 18294609
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association between BRCA1 and BRCA2 mutations and cancer phenotype in Spanish breast/ovarian cancer families: implications for genetic testing.
    de la Hoya M; Osorio A; Godino J; Sulleiro S; Tosar A; Perez-Segura P; Fernandez C; Rodríguez R; Díaz-Rubio E; Benítez J; Devilee P; Caldés T
    Int J Cancer; 2002 Feb; 97(4):466-71. PubMed ID: 11802208
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 'Polygenic' analyses may sharpen disease risk predictions.
    Kaiser J
    Science; 2019 Dec; 366(6472):1431. PubMed ID: 31857459
    [No Abstract]   [Full Text] [Related]  

  • 39. BRCA1 and BRCA2 cancer risks.
    Antoniou AC; Pharoah PD; Easton DF; Evans DG
    J Clin Oncol; 2006 Jul; 24(20):3312-3; author reply 3313-4. PubMed ID: 16829658
    [No Abstract]   [Full Text] [Related]  

  • 40. Diagnostic criteria for testing for BRCA1 and BRCA2: the experience of the Department of Defense Familial Breast/Ovarian Cancer Research Project.
    Fries MH; Holt C; Carpenter I; Carter CL; Daniels J; Flanagan J; Murphy K; Hailey BJ; Martin L; Hume R; Hudson G; Cadman M; Weatherly R; Nunes ME
    Mil Med; 2002 Feb; 167(2):99-103. PubMed ID: 11873550
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.